```
L2   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:246563  CAPLUS
DN   134:266198
TI   Preparation of N-arylsulfonyl amino acid derivatives as c-Jun N-terminal
     kinase inhibitors
IN   Arkinstall, Stephen
PA   Applied Research Systems ARS Holding N.V., Neth. Antilles
SO   Eur. Pat. Appl., 29 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     --------------     ----  --------       ---------------  --------
PI   EP 1088815         A1    20010404       EP 1999-810871   19990928
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
     WO 2001023379      A1    20010405       WO 2000-IB1382   20000928 <--
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
            HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
            LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
            SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
            YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1218375         A1    20020703       EP 2000-960922   20000928
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003510320      T2    20030318       JP 2001-526531   20000928
PRAI EP 1999-810871     A     19990928
     WO 2000-IB1382     W     20000928
OS   MARPAT 134:266198
RE.CNT  15    THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> analyze l2
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L3          ANALYZE L2 1 RN :      17 TERMS

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   14.57      14.78

FILE 'REGISTRY' ENTERED AT 17:51:36 ON 26 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUN 2003  HIGHEST RN 537653-06-8
DICTIONARY FILE UPDATES:  25 JUN 2003  HIGHEST RN 537653-06-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
```

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> s l3
L4 17 L3

=> d 1-17

L4 ANSWER 1 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-90-3** REGISTRY
CN 2-Thiophenesulfonyl chloride, 5-[(di-2-propenylamino)methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-((Diallylamino)methyl)thiophene-2-sulfonyl chloride
FS 3D CONCORD
MF C11 H14 Cl N O2 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1957 TO DATE)
6 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 2 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-89-0** REGISTRY
CN 2-Thiophenemethanamine, N,N-di-2-propenyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Diallyl [[thiophen-2-yl]methyl]amine
FS 3D CONCORD
MF C11 H15 N S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1957 TO DATE)
6 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 3 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-88-9** REGISTRY
CN Glycine, N-[[5-[[(4-chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C14 H13 Cl N2 O5 S2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 4 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-87-8** REGISTRY
CN Glycine, N-[[5-[[(4-chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H21 Cl N2 O5 S2
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 5 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-86-7** REGISTRY
CN Benzamide, 4-chloro-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-Chloro-N-thiophen-2-ylmethylbenzamide
FS 3D CONCORD
MF C12 H10 Cl N O S
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1957 TO DATE)
6 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 6 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-85-6** REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-oxo-2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]ethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 Cl F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 7 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-84-5** REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-oxo-2-[[2-[[3-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]ethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 Cl F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 8 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-83-4** REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-2-oxoethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H21 Cl N6 O6 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 9 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **332082-82-3** REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-[[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-2-oxoethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H20 Cl2 F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 10 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **291756-39-3** REGISTRY
CN Kinase (phosphorylating), gene c-jun protein N-terminal, 3 (9CI) (CA INDEX NAME)
OTHER NAMES:
CN c-Jun N-terminal kinase 3
CN Gene c-jun protein N-terminal kinase 3
CN JNK3
CN JNK3 kinase
CN JNK3 protein kinase
CN Jun N-terminal kinase 3
CN Mitogen-activated protein kinase 10
CN Protein kinase JNK3
CN Protein kinase MAPK10
MF Unspecified
CI MAN
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
83 REFERENCES IN FILE CA (1957 TO DATE)
84 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 11 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **289899-93-0** REGISTRY
CN Kinase (phosphorylating), gene c-jun protein N-terminal, 2 (9CI) (CA INDEX NAME)
OTHER NAMES:
CN c-Jun N-terminal kinase 2
CN Gene c-jun protein N-terminal kinase 2
CN JNK-55 protein kinase
CN JNK2
CN JNK2 kinase
CN JNK2 protein kinase
CN Jun N-terminal kinase 2
CN p54 c-Jun N-terminal kinase

CN P54 c-Jun NH2-terminal kinase
CN p54JNK kinase
CN p55JNK kinase
CN Protein kinase JNK2
CN Protein kinase p54JNK
MF Unspecified
CI MAN
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
237 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
237 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 12 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **219478-19-0** REGISTRY
CN 1,2-Ethanediamine, N-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C8 H9 Cl F3 N3
CI COM
SR CA
LC STN Files: CA, CAPLUS, CHEMCATS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 13 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **166964-34-7** REGISTRY
CN 2-Thiophenesulfonyl chloride, 5-[[(4-chlorobenzoyl)amino]methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(((4-Chlorobenzoyl)amino)methyl)-2-thiophenesulfonyl chloride
CN 5-[(4-Chlorobenzamido)methyl]thiophene-2-sulfonyl chloride
CN 5-[N-(4-Chlorobenzoyl)aminomethyl]thiophene-2-sulfonyl chloride
CN 5-[[[1-(4-Chlorophenyl)methanoyl]amino]methyl]thiophene-2-sulfonyl chloride
FS 3D CONCORD
MF C12 H9 Cl2 N O3 S2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPAT2, USPATFULL





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

15 REFERENCES IN FILE CA (1957 TO DATE)
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L4 ANSWER 14 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **27757-85-3** REGISTRY
CN 2-Thiophenemethanamine (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Thenylamine (6CI, 7CI, 8CI)
OTHER NAMES:
CN (Thiophen-2-ylmethyl)amine
CN 2-Aminomethylthiophene
CN 2-Thienylmethylamine
CN 2-Thiophenemethylamine
FS 3D CONCORD
MF C5 H7 N S
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

360 REFERENCES IN FILE CA (1957 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
362 REFERENCES IN FILE CAPLUS (1957 TO DATE)
4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 15 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **27532-96-3** REGISTRY
CN Glycine, 1,1-dimethylethyl ester, hydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Glycine, tert-butyl ester, hydrochloride (7CI, 8CI)
OTHER NAMES:
CN Glycine tert-butyl ester hydrochloride
CN tert-Butylglycinate hydrochloride
MF C6 H13 N O2 . Cl H
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (6456-74-2)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

283 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
284 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 16 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **122-01-0** REGISTRY
CN Benzoyl chloride, 4-chloro- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzoyl chloride, p-chloro- (6CI, 7CI, 8CI)
OTHER NAMES:
CN 4-Chlorobenzoic acid chloride
CN 4-Chlorobenzoyl chloride
CN p-Chlorobenzoyl chloride
CN para-Chlorobenzoyl chloride
FS 3D CONCORD
MF C7 H4 Cl2 O
LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2724 REFERENCES IN FILE CA (1957 TO DATE)
22 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2728 REFERENCES IN FILE CAPLUS (1957 TO DATE)
30 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 17 OF 17 REGISTRY COPYRIGHT 2003 ACS
RN **106-95-6** REGISTRY
CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propene, 3-bromo- (8CI)
OTHER NAMES:
CN 1-Bromo-2-propene
CN 2-Propenyl bromide

CN 3-Bromo-1-propene
CN 3-Bromopropene
CN 3-Bromopropylene
CN 37: PN: WO03037338 PAGE: 58 claimed sequence
CN Allyl bromide
FS 3D CONCORD
MF C3 H5 Br
CI COM
LC STN Files: ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DETHERM*, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

11502 REFERENCES IN FILE CA (1957 TO DATE)
177 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
11542 REFERENCES IN FILE CAPLUS (1957 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> d  l5
L5 HAS NO ANSWERS
L5                STR
```




```
REP G1=(0-5) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  22  27
NUMBER OF NODES IS  23

STEREO ATTRIBUTES: NONE


=> s l5 ful
FULL SEARCH INITIATED 17:58:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      71 TO ITERATE

100.0% PROCESSED       71 ITERATIONS                                15 ANSWERS
SEARCH TIME: 00.00.01

L7             15 SEA SSS FUL L5

=> s l7 not l4
L8             11 L7 NOT L4

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   182.79     197.57

FILE 'CAPLUS' ENTERED AT 17:58:48 ON 26 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Jun 2003  VOL 138 ISS 26
FILE LAST UPDATED: 25 Jun 2003  (20030625/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l8
L9            8 L8

=> d bib abs hitstr 1-8

L9   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:521684  CAPLUS
DN   137:88483
TI   Hydrophobic polyamine analogs and methods for their use
IN   Burns, Mark Robert; Graminski, Gerard F.; Banduir, Nand
PA   Oridigm Corporation, USA
SO   PCT Int. Appl., 91 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2002053519      A2   20020711       WO 2002-US347    20020108
     WO 2002053519      A3   20030313
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2001-260415P   P    20010108
OS   MARPAT 137:88483
AB   The invention provides polyamine analogs and derivs. contg. a hydrophobic
     region and a polyamine region, as well as methods and compns. for their
     use.  The compds. of the invention can be used e.g. to treat cancer
     osteoporosis, asthma, etc.
IT   330162-58-8
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (hydrophobic polyamine analogs and use)
RN   330162-58-8  CAPLUS
CN   Benzamide, N-[[5-[[[(5S)-5-amino-6-[[3-[[4-[(3-
     aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-
     thienyl]methyl]-4-chloro- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```






L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:886056 CAPLUS
DN 136:15226
TI Novel polyamine transport-inhibiting polyamine analogues as therapeutic and diagnostic agents
IN Vermeulin, Nicolaas M. J.; O'day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PA Oridigm Corporation, USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001092218	A2	20011206	WO 2001-US17795	20010531
	WO 2001092218	A3	20030327		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1317424	A2	20030611	EP 2001-946044	20010531
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 2000-584175 A 20000531
WO 2001-US17795 W 20010531
GI



I

AB Novel "bispolyamine" inhibitor compds. of polyamine transport are disclosed. These compds. are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty

injury. These compds. display desirable activities both for diagnostic and research assays and therapy. Most of the spermine dimers that have been tested provided very good Ki for transport inhibition with values under 75 nM. ORI 1236 (I) was the most potent inhibitor with a Ki of 22 nM. The results were generally mirrored in the growth inhibition assay. All of the compds. were synergistic with difluoromethylornithine, a polyamine synthesis inhibitor, with IC50 values of 10 .mu.M or less.

IT **220221-41-0 220221-56-7 287968-56-3 330162-48-6 330162-52-2**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel polyamine transport-inhibiting polyamine analogs as therapeutic and diagnostic agents)

RN 220221-41-0 CAPLUS
CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 220221-56-7 CAPLUS
CN Benzamide, 4-chloro-N-[[5-[[(6-oxo-7,11,16,20-tetraazadocos-1-yl)amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 287968-56-3 CAPLUS
CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330162-48-6 CAPLUS
CN Benzamide, N-[[5-[[[3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-3-oxopropyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330162-52-2 CAPLUS
CN Benzamide, N-[[5-[[[(1S)-1-[[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]carbonyl]-2-methylpropyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:730681 CAPLUS
DN 135:272682
TI Polyamine analogues as cytotoxic agents
IN Burns, Mark R.
PA Oridigm Corporation, USA
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072685	A2	20011004	WO 2001-US40360	20010323
	WO 2001072685	A3	20020718		
	WO 2001072685	C2	20021010		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1296931	A2	20030402	EP 2001-925146	20010323
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003045755	A1	20030306	US 2002-239521	20020923
PRAI	US 2000-191839P	P	20000324		
	WO 2001-US40360	W	20010323		

OS MARPAT 135:272682
GI



I

AB Novel cytotoxic polyamine analogs are disclosed. These analogs are useful pharmaceutical agents for treating diseases where it is desired to inhibit cell growth and/or proliferation, for example cancer and post-angioplasty injury. Thus, I (ORI 1313) is prepd. and inhibited A375 melanoma growth

36% in mice.

IT **330163-38-7P 330163-49-0P 330163-51-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyamine analogs as cytotoxic agents)

RN 330163-38-7 CAPLUS
CN Benzamide, N,N'-[(6,21-dioxo-7,11,16,20-tetraaza-1,25-pentacosanediyl)bis(iminosulfonyl-5,2-thiophenediylmethylene)]bis[4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 330163-49-0 CAPLUS
CN 2,6,11,15-Tetraazaheneicosanoic acid, 21-[[[5-[[(4-chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]amino]-16-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330163-51-4 CAPLUS
CN 2,6,11,15-Tetraazaheneicosanoic acid, 21-[[[5-[[(4-

chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]amino]-16-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:283950 CAPLUS
DN 134:295844
TI Preparation of amino lactam sulfonamides as inhibitors of A.beta.-protein production
IN Thompson, Lorin Andrew; Han, Amy Qi
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027108	A1	20010419	WO 2000-US27666	20001007
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1218377	A1	20020703	EP 2000-970627	20001007
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	US 6503901	B1	20030107	US 2000-684718	20001007
PRAI	US 1999-158565P	P	19991008		
	WO 2000-US27666	W	20001007		

OS MARPAT 134:295844
GI



I



II

AB The title compds. [I; Q = alkyl, cycloalkyl, etc.; R2 = H, alkyl, alkoxyalkyl, etc.; R5 = H, alkyl, alkoxy, etc.; R5a = H, alkyl; R6 = H, alkyl, aryl, etc.; ring B = 6-8 membered (un)satd. (un)substituted lactam which optionally contains heteroatom; W = (CR8R8a)p; p = 0-4; R8, R8a = H, F, alkyl, etc.; X = a bond, aryl, cycloalkyl, etc.; Y = a bond, alkylene, etc.; Z = H, alkyl, alkenyl, etc.] which inhibit the processing of amyloid precursor protein and, more specifically, inhibit the prodn. of A.beta.-peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein, were prepd. E.g., a 3-step synthesis of II was given. More particularly, the present invention relates to the treatment of neurol. disorders related to .beta.-amyloid prodn. such as Alzheimer's disease and Down's Syndrome. Also, method for inhibiting .gamma.-secretase activity was claimed.

IT **334870-26-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino lactam sulfonamides as inhibitors of A.beta.-protein prodn.)

RN 334870-26-7 CAPLUS

CN Benzamide, N-[[5-[[[(1S)-1-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-3-methylbutyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2001:283935 CAPLUS

DN 134:311233
TI Amino lactam sulfonamides as inhibitors of amyloid-.beta. protein production
IN Thompson, Lorin Andrew
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027091	A1	20010419	WO 2000-US27665	20001007
	W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1222176	A1	20020717	EP 2000-970626	20001007
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	US 6503901	B1	20030107	US 2000-684718	20001007
PRAI	US 1999-158565P	P	19991008		
	WO 2000-US27665	W	20001007		

OS MARPAT 134:311233
GI



I



II

AB This invention relates to prepn. of novel lactams, particularly benzo[e][1,4]diazepines (I) [wherein Q = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbocyclyl, aryl, or heterocyclyl; R2 = H or (un)substituted (alkoxy)alkyl, carbocyclyl(methyl), aryl(methyl), arylethyl, or heterocyclyl; R5 and R5a combine to form a 3-7 membered (un)substituted cycloalkyl or benzo-fused ring; R6 = H or (un)substituted alkyl, carbocyclyl, or aryl; ring B = 6-8 membered (un)substituted lactam, optionally contg. N, NH, NR10, O, S, SO, or SO2; R10 = H, acyl, carboxy (ester), carbamoyl, sulfamoyl, (un)substituted alkyl, aryl, carbocyclyl, heterocyclyl, etc.; W = (CR8R8a)p; p = 0-4; R8 and R8a = independently H, F, (cyclo)alkyl, alkenyl, or alkynyl; X = a bond or (un)substituted aryl, cycloalkyl, carbocycyl, or heterocyclyl; Y = a bond or (CR9R9a)tV(CR9R9a)u; R9 and R9a = independently H, F, or (cycloalkyl); t and u = independently 0-3; V = a bond, CO, O, S, SO, SO2, CO2, OCO or

(un)substituted NH, CONH, NHCO, NHCO2, SO2NH, NHSO, or SONH; Z = H or (un)substituted alkyl, alkenyl, alkynyl, aryl, carbocyclyl, or heterocyclyl] and their pharmaceutical compns. These novel compds. inhibit the processing of amyloid precursor protein and, more specifically, inhibit the prodn. of amyloid-.beta. (A.beta.) peptide, thereby acting to prevent the formation of neurol. deposits of amyloid protein (no data). More particularly, the present invention relates to the treatment of neurol. disorders related to .beta.-amyloid prodn., such as Alzheimer's disease and Down's Syndrome (no data). For example, 3-amino-1-methyl-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one was coupled with N-Boc-L-leucine, deprotected using TFA, and coupled with 3,5-dimethylisoxazole-4-sulfonyl chloride to give II.

IT **334870-26-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amino lactam sulfonamides as inhibitors of a.beta. protein prodn.)

RN 334870-26-7 CAPLUS

CN Benzamide, N-[[5-[[[(1S)-1-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-3-methylbutyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:207925 CAPLUS
DN 134:237682
TI Novel polyamine analogues as therapeutic and diagnostic agents
IN Vermeulin, Nicholaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.
PA Oridigm Corporation, USA
SO Eur. Pat. Appl., 140 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1085011	A1	20010321	EP 2000-308049	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001172244	A2	20010626	JP 2000-282752	20000918
PRAI US 1999-396523	A	19990915		

AB Novel inhibitors of polyamine transport having inhibition consts. two orders of magnitude lower than those of known compds. are disclosed. These polyamine analogs are useful pharmaceutical agents for treating disease where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty

injury. Novel chem. synthetic methods to obtain polyamine analogs are disclosed, including the prodn. of a combinatorial polyamine library. These approaches yield analogs with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system.

IT **220221-41-0P 287968-56-3P 330162-38-4P**
330162-48-6P 330162-52-2P 330162-58-8P
330163-38-7P 330163-49-0P 330163-51-4P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyamines as therapeutic and diagnostic agents)

RN 220221-41-0 CAPLUS
CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 287968-56-3 CAPLUS
CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330162-38-4 CAPLUS
CN Benzamide, N-[[5-[[(21-amino-6-oxo-7,11,16,20-tetraazaheneicos-1-yl)amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330162-48-6 CAPLUS
CN Benzamide, N-[[5-[[[3-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-3-oxopropyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330162-52-2 CAPLUS
CN Benzamide, N-[[5-[[[(1S)-1-[[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]carbonyl]-2-methylpropyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 330162-58-8 CAPLUS
CN Benzamide, N-[[5-[[[(5S)-5-amino-6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 330163-38-7 CAPLUS
CN Benzamide, N,N'-[(6,21-dioxo-7,11,16,20-tetraaza-1,25-pentacosanediyl)bis(iminosulfonyl-5,2-thiophenediylmethylene)]bis[4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 330163-49-0 CAPLUS
CN 2,6,11,15-Tetraazaheneicosanoic acid, 21-[[[5-[[(4-chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]amino]-16-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 330163-51-4 CAPLUS
CN 2,6,11,15-Tetraazaheneicosanoic acid, 21-[[[5-[[(4-chlorobenzoyl)amino]methyl]-2-thienyl]sulfonyl]amino]-16-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **220221-56-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of polyamines as therapeutic and diagnostic agents)

RN 220221-56-7 CAPLUS

CN Benzamide, 4-chloro-N-[[5-[[(6-oxo-7,11,16,20-tetraazadocos-1-yl)amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 2000:553544 CAPLUS

DN 133:164201

TI Preparation of agmatine and polyamine analogs as antizyme modulators for use as drugs and agricultural agents

IN Vermeulin, Nicolaas M. J.; Burns, Mark R.; Webb, Heather K.

PA Oridigm Corporation, USA

SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000046187	A2	20000810	WO 2000-US2972	20000204
	WO 2000046187	A3	20001214		
	W: AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1159261	A2	20011205	EP 2000-913365	20000204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002536357	T2	20021029	JP 2000-597259	20000204
PRAI	US 1999-118892P	P	19990205		
	WO 2000-US2972	W	20000204		

AB A polyamine analog of spermine comprising of four amine groups capable of forming four pos. charges at physiol. pH, wherein the first and second amine groups, and the third and fourth amine groups, are sepd. by the distance of four cC-C and or C-N bonds and the second and third amine are sepd. by the distance of five C-C and/or C-N bonds or more; wherein the the second and third amines are sepd. by a straight or branched

C2-10-alkyl, -alkenyl, -alkynyl, alkoxy, aliph.; C3-10-alicyclic, single or multi-ring arom. or aryl; aryl-substituted alkyl, alkenyl, alkynyl; multiring aryl-substituted aliph.; aliph.-substituted single or multi-ring arom.; alkyl-, alkenyl-, alkynyl-substituted aryl; single or multi-ring heterocyclic; single or multi-ring heterocyclic-substituted aliph.; aliph.-substituted arom.; heterocyclic-substituted alkyl, alkenyl, alkynyl; alkyl-, alkenyl-, alkynyl-substituted heterocycle and wherein said analog induces expression of full-length antizyme. The present invention is directed to agmatine and polyamine analogs and their use as drugs, as well as agricultural or environmentally useful agents. As drugs, the analogs decrease cellular polyamine levels, possibly by inducing antizyme, and can be used to treat disorders of undesired cell proliferation, including cancer, viral infections and bacterial infections. The analogs may be utilized in pharmaceutical compns. either alone or in combination with other agents, particularly other inhibitors of polyamine synthesis or transport, but including other inhibitors of cell proliferation. The analogs are not necessarily metabolized to contribute to the polyamine pool and are designed to enter cells by pathways independent of polyamine transport. The invention further defines structural elements/motifs within these analogs that are key to their induction of antizyme.

IT **287968-56-3P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of agmatine and polyamine analogs as antizyme modulators for use as drugs and agricultural agents)

RN 287968-56-3 CAPLUS

CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1999:77533 CAPLUS

DN 130:153469

TI Novel polyamine analogs as therapeutic and diagnostic agents

IN Vermeulin, Nicolaas M. J.; O'Day, Christine L.; Webb, Heather K.; Burns, Mark R.; Bergstrom, Donald E.

PA Oridigm Corporation, USA

SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9903823	A2	19990128	WO 1998-US14896	19980715
	WO 9903823	A3	19990408		
	W: AL, AM, AU, AZ, BA, BB, BG, BR, CA, CN, CU, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9884968	A1	19990210	AU 1998-84968	19980715
	AU 758570	B2	20030327		
	EP 1001927	A2	20000524	EP 1998-935790	19980715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001510181	T2	20010731	JP 2000-503054	19980715
	US 6172261	B1	20010109	US 1999-341400	19990903
PRAI	US 1997-52586P	P	19970715		
	US 1997-65728P	P	19971114		
	US 1998-85538P	P	19980515		
	WO 1998-US14896	W	19980715		

OS MARPAT 130:153469

GI



I

AB Title inhibitors RXR1 [R =H, or is a head group consisting of a straight or branched C1-10 aliph., alicyclic, single or multiring arom., single or multiring aryl substituted aliph., etc.; R1 is a polyamine; X = CO, NHCO, NHCS, SO2] and pharmaceutical acceptable salts of polyamine transport having inhibition consts. two orders of magnitude lower than those of known compds. are disclosed. These polyamine analogs are useful pharmaceutical agents for treating diseases where it is desired to inhibit polyamine transport or other polyamine binding proteins, for example cancer and post-angioplasty injury and the introduction of a 3-amidopropyl group to the diaminobutyl part of spermidine produce a significantly better transport inhibitor. Novel chem. synthetic methods to obtain polyamine analogs are disclosed, including the prodn. of a combinatorial polyamine library. These approaches yield analogs with desirable activities both for diagnostic and research assays and therapy. The assays of the invention are useful for high throughput screening of targets in the discovery of drugs that interact with the polyamine system. Thus, I was prepd. from 1-aminoanthracene, 4-nitrophenyl chloroformate, and spermine.

IT **220221-41-0P 220221-56-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of polyamines as therapeutic and diagnostic agents)

RN 220221-41-0 CAPLUS
CN Benzamide, N-[[5-[[[6-[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]-6-oxohexyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 220221-56-7 CAPLUS
CN Benzamide, 4-chloro-N-[[5-[[(6-oxo-7,11,16,20-tetraazadocos-1-yl)amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



AN 1997:234254 CAPLUS
DN 126:225111
TI Hydroxamic acid derivatives useful for inhibiting gelatinase
IN Sakaki, Katsuhito; Kanazawa, Hidekazu; Sugiura, Tsuneyuki; Miyazaki, Tohru; Ohno, Hiroyuki
PA Ono Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 757984	A1	19970212	EP 1996-305805	19960807 <--
	EP 757984	B1	20021030		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09104672	A2	19970422	JP 1996-221749	19960805 <--
	US 6022893	A	20000208	US 1996-694473	19960807
	AT 226936	E	20021115	AT 1996-305805	19960807
	ES 2185750	T3	20030501	ES 1996-305805	19960807
PRAI	JP 1995-222673	A	19950808		

OS MARPAT 126:225111
GI



I



II



III

AB The invention relates to hydroxamic acid derivs. I [wherein R1 = H, or C1-4 alkyl; R2 = H, C1-8 alkyl, Ph, C1-4 alkyl substituted by Ph; E = CONR3, in which R3 = H, C1-4 alkyl, etc., NR3CO, CO2, OCO, etc; A = H, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J = bond, C2-4 alkylene, etc.; G = (CH2)m, in which m = 2, 3, or 4, or CR6R7 in which R6 and R7 = H, C1-8 alkyl, etc.] and non-toxic salts thereof, as well as processes for their prepn., and pharmaceutical agents contg. them. I are useful for prevention and/or treatment of diseases induced by overexpression or excess activity of gelatinases, for example, rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis,

interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, corneal injury, metastasis/invasion/growth of tumor cells, autoimmune disease (Crohn's disease, Sjogren's syndrome, etc.), diseases caused by vascular emigration or infiltration of leukocytes, or arterialization, in animals and esp. in human beings. Approx. 13 I were prepd., and test results for 4 compds. are given. For instance, 4-O2NC6H4SO2Cl reacted with H2NCH2CO2CMe3.HCl in pyridine to give 4-O2NC6H4SO2NHCH2CO2CMe3, which underwent a sequence of hydrogenation to the amine, amidation with 4-MeC6H4COCl, deprotection of the tert-Bu ester with aq. CF3CO2H, amidation of the resultant acid with PhCH2ONH2.HCl, and hydrogenolytic debenzylation, to give title compd. II. In a test for inhibition of human gelatinase A in vitro, title compd. III had an IC50 of 0.00023 .mu.M.

=> d hitstr 7

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2003 ACS

IT **188131-43-3P 188131-44-4P 188131-45-5P**
188131-46-6P 188131-47-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of hydroxamic acid derivs. as gelatinase inhibitors)

RN 188131-43-3 CAPLUS

CN Benzamide, 4-methyl-N-[4-[[[2-oxo-2-[(phenylmethoxy)amino]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-44-4 CAPLUS

CN Benzamide, N-[4-[[[2-oxo-2-[(phenylmethoxy)amino]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-45-5 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[[[2-oxo-2-[(phenylmethoxy)amino]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-46-6 CAPLUS

CN Benzenepropanamide, .alpha.-[[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]amino]-N-(phenylmethoxy)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188131-47-7 CAPLUS
CN 1H-Indole-3-propanamide, .alpha.-[[[4-[(4-methylbenzoyl)amino]phenyl]sulfonyl]amino]-N-(phenylmethoxy)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **188131-48-8P 188131-49-9P 188131-50-2P**
188131-51-3P 188131-52-4P 188131-53-5P
188131-54-6P 188131-55-7P 188131-56-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of hydroxamic acid derivs. as gelatinase inhibitors)
RN 188131-48-8 CAPLUS
CN Benzamide, N-[4-[[[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 188131-49-9 CAPLUS
CN Benzamide, N-[4-[[[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-50-2 CAPLUS
CN Benzamide, N-[4-[[[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 188131-51-3 CAPLUS
CN Benzenepropanamide, N-hydroxy-.alpha.-[[[4-[(4-pentylbenzoyl)amino]phenyl]sulfonyl]amino]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188131-52-4 CAPLUS
CN 1H-Indole-3-propanamide, N-hydroxy-.alpha.-[[[4-[(4-methylbenzoyl)amino]phenyl]sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 188131-53-5 CAPLUS
CN Benzamide, N-[3-[[[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-54-6 CAPLUS
CN Benzamide, N-[2-[[[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 188131-55-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[[[2-(hydroxyamino)-1-methyl-2-oxoethyl]amino]sulfonyl]phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188131-56-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[[[2-(hydroxyamino)-1-methyl-2-oxoethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


O
S
C
NH
O
S
NH
CH
C
O
NH
OH
O
Me

AN 1999:556750 CAPLUS
DN 131:184758
TI Preparation of benzenesulfonylamine derivatives as matrix metalloproteinase inhibitors
IN Toyama, Takeshi; Toyama, Itaru; Yagisawa, Takashi; Noda, Atsushi; Kobayashi, Yoshinori
PA Kotobuki Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11236369	A2	19990831	JP 1998-40122	19980223 <--
PRAI JP 1998-40122		19980223		

OS MARPAT 131:184758
GI



I

AB The title compds. R2CH2N(CH2R1)SO2A [R1 = alkyl, etc.; R2 = CO2H, etc.; A = R4R5, etc.; R4 = phenylene, etc.; R5 = (un)substituted Ph, thienyl] are prepd. The title compd. I in vitro showed IC50 of 2.9 x 10-7 M against MMP-2.

IT **240415-88-7P 240415-97-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzenesulfonylamine derivs. as matrix metalloproteinase inhibitors)

RN 240415-88-7 CAPLUS
CN Benzamide, N-[4-[[[2-(hydroxyamino)-2-oxoethyl](2-methylpropyl)amino]sulfonyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 240415-97-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[[(cyclohexylmethyl)[2-(hydroxyamino)-2-oxoethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT **240416-33-5P 240416-35-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzenesulfonylamine derivs. as matrix metalloproteinase inhibitors)

RN 240416-33-5 CAPLUS
CN Benzamide, 4-methoxy-N-[4-[[(2-methylpropyl)[2-oxo-2-[(phenylmethoxy)amino]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 240416-35-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-methoxy-N-[4-[[(2-methylpropyl)[2-oxo-2-[(phenylmethoxy)amino]ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



AN 1991:608506 CAPLUS
DN 115:208506
TI Some novel sulfanilyl amino acid derivatives
AU El-Sayed, Ragab A.
CS Fac. Sci., Al-Azhar Univ., Nasr, Egypt
SO Journal of the Serbian Chemical Society (**1991**), 56(6), 311-18
CODEN: JSCSEN; ISSN: 0352-5139
DT Journal
LA English
AB The title amino acid derivs. 2,4-Cl2C6H4CONHC6H4SO2R-4 (I; R = X-OH; X = Gly, DL-Ala, .beta.-Ala, Val, DL-Val, Leu, DL-Leu, DL-Ser, Phe, Tyr) were prepd. by coupling of the corresponding amino acids with sulfonyl chloride I (R = Cl). Amino acid derivs I (R = X-OH) were esterified to give esters I (R = X-OMe) or coupled with amino acid esters to give dipeptide esters I (R = X-X1-OMe; X1 = Gly, DL-Ala, Leu). Esters I (R = X-OMe, X-X1-OMe) were also converted to the corresponding hydrazides I (R = X-NHNH2, X-X1-NHNH2). Prepd. amino acid and dipeptide derivs. I were active as bactericides and fungicides.

> d hitstr 9

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2003 ACS
IT **136714-01-7P 136714-02-8P 136714-03-9P**
136714-04-0P 136714-05-1P 136714-06-2P
136714-22-2P 136714-23-3P 136714-24-4P
136714-25-5P 136714-26-6P 136714-27-7P
136714-28-8P 136714-29-9P 136714-30-2P
136714-31-3P 136714-32-4P 136714-33-5P
136714-34-6P 136714-35-7P 136714-36-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and bactericidal and fungicidal activity of)
RN 136714-01-7 CAPLUS
CN Alanine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-02-8 CAPLUS
CN L-Valine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-03-9 CAPLUS
CN Valine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-04-0 CAPLUS
CN L-Leucine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-05-1 CAPLUS
CN Serine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-06-2 CAPLUS
CN L-Tyrosine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-22-2 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-23-3 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-24-4 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-25-5 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl]-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-26-6 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-27-7 CAPLUS
CN Alanine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-28-8 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-29-9 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-30-2 CAPLUS
CN Alanine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl-, hydrazide (9CI) (CA INDEX NAME)



RN 136714-31-3 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-32-4 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-33-5 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-34-6 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-35-7 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-36-8 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, hydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **136714-07-3P 136714-08-4P 136714-09-5P**
136714-10-8P 136714-11-9P 136714-12-0P
136714-13-1P 136714-14-2P 136714-15-3P
136714-16-4P 136714-17-5P 136714-18-6P
136714-19-7P 136714-20-0P 136714-21-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn., hydrazinolysis, and bactericidal and fungicidal activity of)

RN 136714-07-3 CAPLUS

CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 136714-08-4 CAPLUS

CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-09-5 CAPLUS

CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-10-8 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 136714-11-9 CAPLUS
CN Glycine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-12-0 CAPLUS
CN Alanine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl-, methyl ester (9CI) (CA INDEX NAME)



RN 136714-13-1 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-14-2 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-15-3 CAPLUS
CN Alanine, N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl-, methyl ester (9CI) (CA INDEX NAME)



RN 136714-16-4 CAPLUS
CN Alanine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-17-5 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]alanyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-18-6 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-19-7 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-leucyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-20-0 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]leucyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 136714-21-1 CAPLUS
CN L-Leucine, N-[N-[[4-[(2,4-dichlorobenzoyl)amino]phenyl]sulfonyl]-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


O
MeO
S
Bu-i
NH
O
OH
O
O
S
N
H
S
Cl
O
N
H
Cl

```
=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
REP G1=(0-3) CH2
NODE ATTRIBUTES:
NSPEC   IS R      AT  10
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   5
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE


=> s l1 ful
FULL SEARCH INITIATED 16:23:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  16325 TO ITERATE

100.0% PROCESSED   16325 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

L3             2 SEA SSS FUL L1

=> d 1-2

L3   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2003 ACS
RN   103891-80-1  REGISTRY
CN   Benzamide, N-[4-[[[5-amino-1-[[4-(phenylmethyl)-1-
     piperidinyl]carbonyl]pentyl]amino]sulfonyl]phenyl]-, (S)- (9CI)  (CA INDEX
     NAME)
FS   STEREOSEARCH
MF   C31 H38 N4 O4 S
SR   CA
LC   STN Files:   CA, CAPLUS

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS
RN 57891-05-1 REGISTRY
CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 Cl N4 O5 S
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	152.71	152.92

FILE 'CAPLUS' ENTERED AT 16:23:35 ON 05 MAR 2003

FILE COVERS 1907 - 5 Mar 2003 VOL 138 ISS 10
FILE LAST UPDATED: 4 Mar 2003 (20030304/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 4 L3

=> d bib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1986:497950 CAPLUS
DN 105:97950
TI Lysine derivative and proteinase inhibitor
IN Okamoto, Shosuke; Okada, Yoshio; Okunomiya, Akiko; Naito, Taketoshi; Yamada, Morihiko; Kimura, Yoshio; Katsuura, Yasuhiro; Suzuki, Hiroshi; Ohno, Norio; Seki, Yumi
PA Showa Denko K. K., Japan
SO Eur. Pat. Appl., 86 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 183271	A2	19860604	EP 1985-115142	19851129
	EP 183271	A3	19870520		
	EP 183271	B1	19900516		
	R: CH, DE, FR, GB, LI, SE				
	JP 61130268	A2	19860618	JP 1984-251985	19841130
	JP 61189255	A2	19860822	JP 1985-26556	19850215
	JP 61218565	A2	19860929	JP 1985-56153	19850322
	JP 62005945	A2	19870112	JP 1985-143852	19850702
PRAI	JP 1984-251985		19841130		
	JP 1985-26556		19850215		
	JP 1985-56153		19850322		
	JP 1985-143852		19850702		

AB Lysines R1Z1-Lys-R2 (R1 = carbocyclic or heterocyclic aryl; Z1 = SO2, CO; R2 = NH2, substituted amino), which were prepd., showed plasmin inhibition activity. N2-(p-Toluenesulfonyl)-L-lysine 4-benzylpiperidide was prepd. from N6-(benzyloxycarbonyl)lysine in a series of reactions.
IT **103891-80-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as plasmin inhibitor)
RN 103891-80-1 CAPLUS
CN Benzamide, N-[4-[[[5-amino-1-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]pentyl]amino]sulfonyl]phenyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1977:484998 CAPLUS
DN 87:84998
TI Pyrazole derivatives
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Fr. Demande, 21 pp.
CODEN: FRXXBL
DT Patent

LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2312242	A1	19761224	FR 1975-16940	19750530
	FR 2312242	B1	19800430		
PRAI	FR 1975-16940		19750530		

GI



AB Pyrazoles I [R = MeCONHCH2CH2, Cl, EtO2CNHCH2CH2, R1 = H, n = 0, 1; R = H, pyrazinylcarboxamidoethyl, R1 = H, n = 1; R = 5,2-Cl(MeO)C6H3CONHCH2CH2, cyclohexyl, Me2CHCH2, R1 = H, n = 0; R = Cl, R1 = Ph, Me, CH2Ph, n = 0] were prepd. by cyclyzing 4-RC6H4SO2NHCHR1(CH2)nCONHNH2 with Ac2CH2. I are antidiabetics. Thus, I [R = 5,2-Cl(MeO)C6H3CONHCH2CH2, R1 = H, n = 0] at 100 mg/kg orally in rats caused a 48.1% decrease in blood sugar level 2 h after administration.

IT **57891-05-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antidiabetic activity of)

RN 57891-05-1 CAPLUS

CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1977:89810 CAPLUS

DN 86:89810

TI Pyrazole derivatives

IN Irikura, Tsutomu

PA Kyorin Pharmaceutical Co., Ltd., Japan

SO Belg., 24 pp.
CODEN: BEXXAL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 829785	A1	19751001	BE 1975-156955	19750602
PRAI	BE 1975-156955		19750602		

GI



I

AB Pyrazoles I (R = H, AcNHCH2CH2, pyrazinnylcarboxamidoethyl, EtO2CNHCH2CH2, Cl, R1 = H, n = 1; R = Cl, AcNHCH2CH2, EtO2CNHCH2CH2, 5,2-Cl(MeO)C6H3CONHCH2CH2, cyclohexyl, Me2CHCH2, R1 = H, n = 0; R = Cl, R1 = Ph, Me, PhCH2, n = 0) were prepd. by condensing 4-RC6H4SO2NHCHR1:CH2)nCONHNH2 with Ac2CH2. I at 100 mg/kg orally in rats gave 22.1-51.3% decrease in blood sugar level.

IT **57891-05-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antidiabetic activity of)

RN 57891-05-1 CAPLUS

CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

AN 1976:59445 CAPLUS

DN 84:59445

TI Antidiabetic pyrazoles

IN Irikura, Tsutomu

PA Kyorin Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 50070367	A2	19750611	JP 1973-121974	19731030
JP 52038033	B4	19770927		
PRAI JP 1973-121974		19731030		

GI For diagram(s), see printed CA Issue.

AB Pyrazoles I [R = 2-acetylaminoethyl (Q), 2-ethoxycarbonylaminoethyl, 2-(2-methoxy-5-chlorobenzoylamino)ethyl, 2-(2-pyrazinecarbonylamino)ethyl (Q1), Me, iso-Bu, cyclohexyl, Cl; R1 = H, Me, Ph, pentyl; n = 0-1 when R1 = H; n = 0 when R1 = Me, Ph, pentyl] were prepd. by reaction of p-RC6H4SO2NHCHR1(CH2)nCONHNH2 with AcCH2Ac. Thus, refluxing 10 g N-benzenesulfonyl-.beta.-alanine hydrazide with 5 g AcCH2Ac in EtOH 3 hr gave 99% I (R = R1 = H, n = 1). Among 15 more I prepd. were the following

I (R, R1, n given): Me, H, 1; Q, H, 1; Q1, H, 1; and Cl, H, 0.

IT **57891-05-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiadiabetic activity of)

RN 57891-05-1 CAPLUS

CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=7/8/9
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 8 4
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 08:02:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 475 TO ITERATE

100.0% PROCESSED 475 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

L3 12 SEA SSS FUL L1

=> d 1-12

L3 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213475-13-9 REGISTRY
CN Glycine, N-[[4-[[(2,4-dichlorobenzoyl)amino]methyl]phenyl]sulfonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H27 Cl2 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213475-12-8 REGISTRY
CN Glycine, N-[[4-[[(2,4-dichlorobenzoyl)amino]methyl]phenyl]sulfonyl]-L-alanyl-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H21 Cl2 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213475-11-7 REGISTRY
CN Glycine, N-[[4-[[(2,4-dichlorobenzoyl)amino]methyl]phenyl]sulfonyl]glycyl-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H19 Cl2 N3 O6 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-98-7 REGISTRY
CN Glycine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H26 Cl N3 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-97-6 REGISTRY
CN Glycine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-L-leucyl-, methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H28 Cl N3 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-96-5 REGISTRY
CN Glycine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]glycyl-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H20 Cl N3 O6 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-94-3 REGISTRY
CN L-Leucine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H25 Cl N4 O4 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-92-1 REGISTRY
CN L-Valine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H23 Cl N4 O4 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-90-9 REGISTRY
CN Alanine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H19 Cl N4 O4 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 213474-88-5 REGISTRY
CN Glycine, N-[[4-[[(4-chlorobenzoyl)amino]methyl]phenyl]sulfonyl]-, hydrazide (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H17 Cl N4 O4 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 91663-07-9 REGISTRY
CN Ethanediamide, N-[[4-[(benzoylamino)methyl]phenyl]sulfonyl]-N'-butyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H23 N3 O5 S
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2003 ACS
RN 91663-06-8 REGISTRY
CN Ethanediamide, {[4-[(benzoylamino)methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 N3 O5 S
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s l3
L4 4 L3

=> d bib abs 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1999:108539 CAPLUS
DN 130:223580
TI A facile synthesis and some new reactions of N-benzylcarboxamides with essential amino acids
AU El-Sayed, Ragab A.
CS Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Egypt
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1998), 37B(10), 1059-1062
CODEN: IJSBDB; ISSN: 0376-4699
PB National Institute of Science Communication, CSIR
DT Journal
LA English
GI



I



II

AB N-benzyl-4-chlorobenzamide and N-benzyl-2,4-dichlorobenzamide react with chlorosulfonic acid to give the corresponding p-sulfonyl chlorides I (X = H, Cl), which on condensation with amino acids give amino acid derivs. II (R = H, Me, CHMe2, CH2CHMe2, CH2Ph, CH2C6H6OH-4; X = H, Cl; Y = OH). Some of the corresponding Me esters II (X = H; R = H, Me, CHMe2, CH2CHMe2; Y = OMe) are also prepd. Hydrazinolysis of these Me esters yield the hydrazides II (X = H; R = H, Me, CHMe2, CH2CHMe2, Y = NHNH2). Coupling reactions of some amino acid derivs. with H-Gly-OMe hydrochloride in THF-Et3N medium using the dicyclohexylcarbodiimide method furnishes the desired dipeptide Me esters II (X = H, Cl; R = H, Me, CH2C6H6OH-4, CH2CHMe2; Y = NHCH2CO2Me). The spectral data are briefly discussed.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1998:659430 CAPLUS
DN 130:38661
TI A facile synthesis and some new reactions of N-benzylcarboxamides with essential amino acids
AU El-Sayed, Ragab A.
CS Chemistry Department, Faculty of Science, Al-Azhar Univ., CAIRO, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (1997), 131, 207-213
CODEN: PSSLEC; ISSN: 1042-6507

PB Gordon & Breach Science Publishers
DT Journal
LA English
AB N-Benzyl-p-chloro- and N-Benzyl-2,4-dichlorobenzamide react with chlorosulfonic acid to give the corresponding p-sulfonyl chlorides, which condensed with nucleophiles to give amino acid derivs. Me esterification, hydrazinolysis, and coupling reactions of the amino acid derivs. are described.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1998:541520 CAPLUS
DN 129:260836
TI A facile synthesis and some new reactions of N-benzylcarboxamides with essential amino acids
AU El-Sayed, Ragab A.
CS Chemistry Department, Faculty of Science, Al-Azhar University, Nasr, Egypt
SO Journal of the Serbian Chemical Society (1998), 63(8), 601-606
CODEN: JSCSEN; ISSN: 0352-5139
PB Serbian Chemical Society
DT Journal
LA English
GI



I

AB N-Benzyl-p-chloro and N-benzyl-2,4-dichlorobenzamide react with chlorosulfonic acid to give the corresponding p-sulfonyl chlorides I (R1 = H, Cl; R2 = Cl) which on condensation with nucleophiles give amino acid derivs. I (R1 = H; R2 = X1-OH; X1 = Gly, DL-Ala, Val, DL-Val, Leu, Tyr; and R1 = Cl; R2 = X2-OH; X2 = Gly, Ala, Val, Leu, Tyr, Phe). Some of the corresponding Me esters I (R1 = H, R2 = X3-OMe; X3 = Gly, DL-Ala, Val, Leu) were also prepd. Hydrazinolysis of these Me esters yielded the hydrazides I (R1 = H, R2 = X3-N2H3; X3 = same). Coupling reactions of some amino acid derivs. with amino acid Me ester hydrochloride in THF-Et3N medium, using the dicylohexylcarbodiimide method, furnished the desired dipeptide Me esters I (R1 = H; R2 = X4-Gly-OMe; X4 = Gly, Leu, Tyr; and R1 = Cl; R2 = X5-Gly-OMe; X5 = Gly, Ala, Leu). The spectral data are briefly discussed.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1984:510479 CAPLUS
DN 101:110479
TI Synthesis and properties of esters of [4-[(acylamido)methyl]benzenesulfonyl]oxamic acids
AU Petyunin, P. A.; Valyashko, N. N.; Shemchuk, L. A.; Konev, V. F.; Stoletov, Yu. V.; Klebanov, B. M.
CS Khar'k. Gos. Farm. Inst., Kharkov, USSR
SO Deposited Doc. (1982), SPSTL 1220 Khp-D82, 9 pp. Avail.: SPSTL
DT Report
LA Russian
AB p-H2NSO2C6H4CH2NHR (I; R = H) reacted with R1COX (R1 = Me, Ph, 4-tolyl,

4-O2NC6H4, 2-ClC6H4; X = halo) and with R2SO2Cl (R2 = Ph, 4-tolyl, 4-AcNHC6H4, 2-ClC6H4, 2-BrC6H4, 4-O2NC6H4) to give 11 corresponding I (R = COR1, SO2R2) (II) in 43-84% yield. II condensed with (CO2Et)2 in MeOH contg. NaOMe to give 56-89% yield of 9 corresponding p-R3COCONHSO2C6H4CH2NHR (III; R3 = EtO), which gave 67-96% III (R = Bz, R3 = H2N, BuNH; R = p-tosyl, R3 = H2N, H2NNH, cyclohexylamino) (IV) with the resp. R3H. IV had hypoglycemic activity (no data).




```
VAR G1=7/8/9
ENTER (DIS), GRA, NOD, BON OR ?:end
L14  STRUCTURE CREATED

=> s l14
SAMPLE SEARCH INITIATED 08:07:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     28 TO ITERATE

100.0% PROCESSED      28 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          243 TO      877
PROJECTED ANSWERS:               0 TO        0

L15            0 SEA SSS SAM L14

=> s l14 ful
FULL SEARCH INITIATED 08:07:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    505 TO ITERATE

100.0% PROCESSED     505 ITERATIONS                               0 ANSWERS
SEARCH TIME: 00.00.01

L16            0 SEA SSS FUL L14
```




```
ENTER (DIS), GRA, NOD, BON OR ?:end
L17  STRUCTURE CREATED

=> s l17
SAMPLE SEARCH INITIATED 08:08:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    887 TO ITERATE

100.0% PROCESSED     887 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        15954 TO    19526
PROJECTED ANSWERS:               0 TO        0

L18            0 SEA SSS SAM L17

=> s l17 ful
FULL SEARCH INITIATED 08:08:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  17448 TO ITERATE

100.0% PROCESSED   17448 ITERATIONS                          0 ANSWERS
SEARCH TIME: 00.00.01

L19            0 SEA SSS FUL L17
```

```
=> d l20
L20 HAS NO ANSWERS
L20             STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT   3
GGCAT   IS MCY  UNS  AT  17
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE


=> s l20 ful
FULL SEARCH INITIATED 08:09:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  17448 TO ITERATE

100.0% PROCESSED   17448 ITERATIONS                          18 ANSWERS
SEARCH TIME: 00.00.01

L22          18 SEA SSS FUL L20

=> s l22 not l3
L23           6 L22 NOT L3

=> d 1-6

L23  ANSWER 1 OF 6  REGISTRY  COPYRIGHT 2003 ACS
RN   334870-26-7  REGISTRY
CN   Benzamide, N-[[5-[[[(1S)-1-[[(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-
     benzodiazepin-3-yl)amino]carbonyl]-3-methylbutyl]amino]sulfonyl]-2-
     thienyl]methyl]- (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C34 H35 N5 O5 S2
SR   CA
LC   STN Files:   CA, CAPLUS, USPATFULL

Absolute stereochemistry.
```





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L23 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 332082-85-6 REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-oxo-2-[[2-[[5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]ethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 Cl F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L23 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 332082-84-5 REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-oxo-2-[[2-[[3-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]ethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H21 Cl F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L23 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 332082-83-4 REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-2-oxoethyl]amino]sulfonyl]-2-thienyl]methyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H21 Cl N6 O6 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L23 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2003 ACS

RN 332082-82-3 REGISTRY
CN Benzamide, 4-chloro-N-[[5-[[[2-[[2-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]amino]ethyl]amino]-2-oxoethyl]amino]sulfonyl]-2-thienyl]methyl]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H20 Cl2 F3 N5 O4 S2
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L23 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2003 ACS
RN 330162-52-2 REGISTRY
CN Benzamide, N-[[5-[[[(1S)-1-[[[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]amino]carbonyl]-2-methylpropyl]amino]sulfonyl]-2-thienyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H43 Cl N6 O4 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)




```
ENTER (DIS), GRA, NOD, BON OR ?:end
L1   STRUCTURE CREATED

=> s l1
SAMPLE SEARCH INITIATED 08:26:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   4280 TO ITERATE

 23.4% PROCESSED    1000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        81678 TO    89522
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 08:26:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  84394 TO ITERATE

100.0% PROCESSED   84394 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.02

L3             3 SEA SSS FUL L1
```

=> s l3
L4 4 L3

=> d bib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1979:121590 CAPLUS
DN 90:121590
TI Novel pyrazole derivatives
IN Irikura, Tsutomu
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Brit., 14 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 1505518	A	19780330	GB 1975-23637	19750530
PRAI GB 1975-23637		19750530		

GI



I

AB The prepn. is described of pyrazoles I [R = AcNH(CH2)2, EtO2CNH(CH2)2, 5,2-Cl(MeO)C6H3CONH(CH2)2, 2-(2-pyrazinecarbonylamino)ethyl, Me2CHCH2, cyclohexyl, Cl; n = 0 or 1 when R1 = H; n = 0 when R1 = Me, Ph, PhCH2]. Thus, I (R = Cl, R1 = H, n = 0) was prepd. (60.3%) by treating 4-ClC6H4SO2NHCH2CONHNH2 with (MeCO)2CH2. Pharmacol. studies showed that I are very useful as antidiabetic agents.

IT **57890-99-0P 69497-54-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(antidiabetic agent, prepn. of)

RN 57890-99-0 CAPLUS
CN Pyrazinecarboxamide, N-[2-[4-[[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 69497-54-7 CAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1977:484998 CAPLUS
DN 87:84998
TI Pyrazole derivatives
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Fr. Demande, 21 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2312242	A1	19761224	FR 1975-16940	19750530
	FR 2312242	B1	19800430		
PRAI	FR 1975-16940		19750530		

GI



AB Pyrazoles I [R = MeCONHCH2CH2, Cl, EtO2CNHCH2CH2, R1 = H, n = 0, 1; R = H, pyrazinylcarboxamidoethyl, R1 = H, n = 1; R = 5,2-Cl(MeO)C6H3CONHCH2CH2, cyclohexyl, Me2CHCH2, R1 = H, n = 0; R = Cl, R1 = Ph, Me, CH2Ph, n = 0] were prepd. by cyclyzing 4-RC6H4SO2NHCHR1(CH2)nCONHNH2 with Ac2CH2. I are antidiabetics. Thus, I [R = 5,2-Cl(MeO)C6H3CONHCH2CH2, R1 = H, n = 0] at 100 mg/kg orally in rats caused a 48.1% decrease in blood sugar level 2 h after administration.

IT **57890-99-0P 57891-05-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antidiabetic activity of)

RN 57890-99-0 CAPLUS
CN Pyrazinecarboxamide, N-[2-[4-[[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 57891-05-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1977:89810 CAPLUS
DN 86:89810
TI Pyrazole derivatives
IN Irikura, Tsutomu
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Belg., 24 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 829785	A1	19751001	BE 1975-156955	19750602
PRAI	BE 1975-156955		19750602		

GI



I

AB Pyrazoles I (R = H, AcNHCH2CH2, pyrazinnylcarboxamidoethyl, EtO2CNHCH2CH2, Cl, R1 = H, n = 1; R = Cl, AcNHCH2CH2, EtO2CNHCH2CH2, 5,2-Cl(MeO)C6H3CONHCH2CH2, cyclohexyl, Me2CHCH2, R1 = H, n = 0; R = Cl, R1 = Ph, Me, PhCH2, n = 0) were prepd. by condensing 4-RC6H4SO2NHCHR1:CH2)nCONHNH2 with Ac2CH2. I at 100 mg/kg orally in rats gave 22.1-51.3% decrease in blood sugar level.

IT **57890-99-0P 57891-05-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antidiabetic activity of)

RN 57890-99-0 CAPLUS
CN Pyrazinecarboxamide, N-[2-[4-[[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 57891-05-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
AN 1976:59445 CAPLUS
DN 84:59445
TI Antidiabetic pyrazoles
IN Irikura, Tsutomu
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50070367	A2	19750611	JP 1973-121974	19731030
	JP 52038033	B4	19770927		
PRAI	JP 1973-121974		19731030		

GI For diagram(s), see printed CA Issue.
AB Pyrazoles I [R = 2-acetylaminoethyl (Q), 2-ethoxycarbonylaminoethyl, 2-(2-methoxy-5-chlorobenzoylamino)ethyl, 2-(2-pyrazinecarbonylamino)ethyl (Q1), Me, iso-Bu, cyclohexyl, Cl; R1 = H, Me, Ph, pentyl; n = 0-1 when R1 = H; n = O when R1 = Me, Ph, pentyl] were prepd. by reaction of p-RC6H4SO2NHCHR1(CH2)nCONHNH2 with AcCH2Ac. Thus, refluxing 10 g N-benzenesulfonyl-.beta.-alanine hydrazide with 5 g AcCH2Ac in EtOH 3 hr gave 99% I (R = R1 = H, n = 1). Among 15 more I prepd. were the following I (R, R1, n given): Me, H, 1; Q, H, 1; Q1, H, 1; and Cl, H, 0.
IT **57890-99-0P 57891-05-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiadiabetic activity of)
RN 57890-99-0 CAPLUS
CN Pyrazinecarboxamide, N-[2-[4-[[[3-(3,5-dimethyl-1H-pyrazol-1-yl)-3-oxopropyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 57891-05-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.98	173.58

AN 1998:87604 CAPLUS
DN 128:167263
TI Preparation of N-(mercaptoethyl)(benzene or alkyl)sulfonamide derivatives or their disulfides as metalloprotease inhibitors
IN Decrescenzo, Gary; Abbas, Zaheer S.; Freskos, John N.; Getman, Daniel P.; Heintz, Robert M.; Mischke, Brent V.; et al.
PA Monsanto Co., USA; Decrescenzo, Gary; Abbas, Zaheer S.; Freskos, John N.; Getman, Daniel P.
SO PCT Int. Appl., 301 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803166	A1	19980129	WO 1997-US12873	19970722
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9738903	A1	19980210	AU 1997-38903	19970722
	AU 740263	B2	20011101		
	BR 9710752	A	19990817	BR 1997-10752	19970722
	EP 939629	A1	19990908	EP 1997-936168	19970722
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1238688	A	19991215	CN 1997-197980	19970722
	NZ 333825	A	20001027	NZ 1997-333825	19970722
	JP 2000515153	T2	20001114	JP 1998-507195	19970722
	NZ 506464	A	20020628	NZ 1997-506464	19970722
	NO 9900247	A	19990319	NO 1999-247	19990120
PRAI	US 1996-22040P	P	19960722		
	NZ 1997-333825	A1	19970722		
	WO 1997-US12873	W	19970722		

OS MARPAT 128:167263
GI



I

AB This invention is directed to proteinase (protease) inhibitors, and more particularly to thiol sulfonamide inhibitors for matrix metalloproteinase (MMP-13), compns. of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, processes for the prepn. of proteinase inhibitors and processes for treating pathol. conditions assocd. with pathol. matrix metalloproteinase activity related to MMP-13. The title compds. are represented by formula HSCH2CHR4N(R2)SO2R1, R9C(:W)SCH2CH(R4)N(R2)SO2R1, or R1SO2N(R2)CH(R4)CH2S-SCH2CH(R4)N(R2)SO2R1 [R1 = a radical having a length greater than that of a satd. four carbon chain and sorter than that of a satd. eighteen carbon chain, and when rotated about an axis drawn through the SO2-bonded 1-position and the 4-position of a 6-membered ring or the SO2-bonded position and substituent-bonded 3- or 5-membered ring defines a three-dimensional vol.

whose widest dimension has the width of about one Ph ring to about three Ph rings in a direction to that axis to rotation; R2 = H, C1-6 alkyl, C2-4 alkyl substituted by amino or mono- or disubstituted amino; R4 = CO2H, CONH2, C1-6 alkyl; W = O, S; R9 = C1-6 alkyl, C1-6 alkoxy, single-ringed carbocyclic or heteroaryl; provided that R2 = H only when R1 = 4-(phenylazo)phenyl]. They are useful for the treatment of the diseases in which known and new MMP enzymes are implicated, e.g. uncontrolled breakdown of connective tissue by metalloproteinases leading to rheumatoid arthritis, osteoarthritis, tumor metastasis, etc. Thus, N-[(R)-2-hydroxy-1-methylethyl]-N-methyl-4-methoxybenzenesulfonamide (prepn. given) underwent Mitsunobu reaction with thioacetic acid using Ph3P and di-Et azodicarboxylate in THF at 0.degree. for 0.5 h followed by treatment with NaOMe in MeOH to give N-[(R)-2-mercapto-1-methylethyl]-N-methyl-4-methoxybenzenesulfonamide (I; R = OMe, R2 = Me, R4 = Me). The latter compd. and I (R = SPh, R2 = Q, R4 = CONH2) in vitro showed IC50 of 300 and 2,060 nM, resp., against MMP-1 and 32.5 and <0.1 nM, resp., against MMP-13.

IT **202752-07-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(mercaptoethyl)(benzene or alkyl)sulfonamide derivs. or their disulfides as metalloprotease inhibitors and therapeutics)

RN 202752-07-6 CAPLUS

CN Benzamide, N-[4-[[[2-amino-2-oxo-1-[[(triphenylmethyl)thio]methyl]ethyl]amino]sulfonyl]phenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 1999:579153 CAPLUS
DN 131:214280
TI Preparation of sulfonamides as MMP-8 inhibitors
IN Watanabe, Fumihiko; Tsumiki, Hiroshige
PA Shionogi and Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11246527	A2	19990914	JP 1998-49260	19980302 <--

PRAI JP 1998-49260 19980302
OS MARPAT 131:214280
GI



I

AB The title compds. R4R3SO2N(R2)CH(R1)COY [R1 = (un)substituted alkyl, etc.; R2 = H, alkyl, etc.; R3 = phenylene, etc.; R4 = (un)substituted phenyl; Y = NHOH, OH] are prepd. The title compd. I at 1000 nM gave 97.6% inhibition of MMP-8. Formulations are given.

IT **243144-02-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonamides as MMP-8 inhibitors)

RN 243144-02-7 CAPLUS
CN Benzamide, N-[4-[[[(1R)-1-[(hydroxyamino)carbonyl]-2-methylpropyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1976:59445 CAPLUS
DN 84:59445
TI Antidiabetic pyrazoles
IN Irikura, Tsutomu
PA Kyorin Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50070367	A2	19750611	JP 1973-121974	19731030
	JP 52038033	B4	19770927		
PRAI	JP 1973-121974		19731030		

GI For diagram(s), see printed CA Issue.
AB Pyrazoles I [R = 2-acetylaminoethyl (Q), 2-ethoxycarbonylaminoethyl, 2-(2-methoxy-5-chlorobenzoylamino)ethyl, 2-(2-pyrazinecarbonylamino)ethyl (Q1), Me, iso-Bu, cyclohexyl, Cl; R1 = H, Me, Ph, pentyl; n = 0-1 when R1 = H; n = 0 when R1 = Me, Ph, pentyl] were prepd. by reaction of p-RC6H4SO2NHCHR1(CH2)nCONHNH2 with AcCH2Ac. Thus, refluxing 10 g N-benzenesulfonyl-.beta.-alanine hydrazide with 5 g AcCH2Ac in EtOH 3 hr gave 99% I (R = R1 = H, n = 1). Among 15 more I prepd. were the following I (R, R1, n given): Me, H, 1; Q, H, 1; Q1, H, 1; and Cl, H, 0.
IT **57891-05-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and antiadiabetic activity of)
RN 57891-05-1 CAPLUS
CN Benzamide, 5-chloro-N-[2-[4-[[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



4/5/1 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci

07916363 Genuine Article#: 223XL Number of References: 56
Title: New targets for anti-inflammatory drugs
Author(s): Lewis AJ (REPRINT) ; Manning AM
Corporate Source: SIGNAL PHARMACEUT INC,5555 OBERLIN DR/SAN DIEGO//CA/92121 (REPRINT)
Journal: CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, V3, N4 (AUG), P489-494
ISSN: 1367-5931 Publication date: 19990800
Publisher: CURRENT BIOLOGY LTD, 34-42 CLEVELAND STREET, LONDON W1P 6LE, ENGLAND
Language: English Document Type: **REVIEW**
Geographic Location: USA
Subfile: CC LIFE--Current Contents, Life Sciences
Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY; BIOPHYSICS
Abstract: Inflammatory and **autoimmune** diseases, including rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis, psoriasis and asthma, provide drug discoverers with a tremendous challenge. The precise causes of these diseases are not known, but our understanding of the molecular and cellular mechanisms associated with inflammatory diseases has increased dramatically. As a consequence, a wide array of gene targets have emerged that control cell influx and activation, inflammatory mediator release and activity, and tissue proliferation and degradation. Since multiple gene products have been identified at the sites of inflammation, there has been a surge of interest in identifying intracellular signaling targets, including transcription factors that control inflammatory gene expression and which are amenable to drug discovery.
Identifiers--KeyWord Plus(R): NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; MAP-KINASE; RHEUMATOID-ARTHRITIS; **JNK** PATHWAY; TNF-ALPHA; T-CELLS; **INHIBITOR**; DISEASE; AP-1

07699439 Genuine Article#: 198ER Number of References: 64
Title: Alkyl-lysophospholipids activate the SAPK **JNK** pathway and **enhance** radiation induced apoptosis
Author(s): Ruiter GA; Zerp SF; Bartelink H; vanBlitterswijk WJ; Verheij M (REPRINT)
Corporate Source: ANTONI VAN LEEUWENHOEK ZIEKENHUIS,NETHERLANDS CANC INST, DEPT RADIOTHERAPY, PLESMANLAAN 121/NL-1066 CX AMSTERDAM//NETHERLANDS/ (REPRINT); ANTONI VAN LEEUWENHOEK ZIEKENHUIS,NETHERLANDS CANC INST, DEPT RADIOTHERAPY/NL-1066 CX AMSTERDAM//NETHERLANDS/; ANTONI VAN LEEUWENHOEK ZIEKENHUIS,NETHERLANDS CANC INST, DIV CELLULAR BIOCHEM/NL-1066 CX AMSTERDAM//NETHERLANDS/
Journal: CANCER RESEARCH, 1999, V59, N10 (MAY 15), P2457-2463
ISSN: 0008-5472 Publication date: 19990515
Publisher: AMER ASSOC CANCER RESEARCH, PO BOX 11806, BIRMINGHAM, AL 35202
Language: English Document Type: ARTICLE
Geographic Location: NETHERLANDS
Subfile: CC LIFE--Current Contents, Life Sciences; CC CLIN--Current Contents, Clinical Medicine
Journal Subject Category: ONCOLOGY
Abstract: Alkyl-lysophospholipids (ALPs) represent a new class of antitumor drugs that induce apoptotic cell death in a variety of tumor cell lines. Although their precise mechanism of action is unknown, ALPs primarily act on the cell membrane, where they inhibit signaling through the mitogen-activated protein kinase (MAPK) pathway. Because stimulation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway is essential for radiation-induced apoptosis in certain cell types, we tested the effect of ALPs in combination with ionizing radiation on MAPK/SAPK signaling and apoptosis induction. Here, we present data showing that three ALPs, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, hexadecylphosphocholine, and the novel compound octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate (D-21266) induce time- and dose-dependent apoptosis in the human leukemia cell lines U937 and Jurkat T but not in normal vascular endothelial cells. Moreover, in combination with radiation, ALPs strongly enhance the induction of apoptosis in both leukemic cell lines. All tested ALPs not only prevented MAPK activation, but, like radiation, stimulated the SAPK/JNK cascade within minutes. A dominant-negative mutant of c-Jun inhibited radiation- and ALP-induced apoptosis, indicating a requirement for the SAPK/**JNK** pathway. Our data support the view that ALPs and ionizing radiation cause an **enhanced** apoptotic effect by modulating the balance between the mitogenic, antiapoptotic MAPK, and the apoptotic SAPK/**JNK** pathways. This type of modulation of specific signal transduction pathways in tumor cells may lead to the development of new **therapeutic** strategies.
Identifiers--KeyWord Plus(R): PROTEIN-KINASE-C; N-TERMINAL KINASE; PROGRAMMED CELL-DEATH; HUMAN LEUKEMIC-CELLS; ETHER LIPID 1-OCTADECYL-2-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE; SIGNAL-TRANSDUCTION; IONIZING-RADIATION; PERSISTENT ACTIVATION; PHOSPHOLIPID ANALOGS; TRANSCRIPTION FACTOR

10905579 Genuine Article#: 582GX Number of References: 49
Title: Bisindolylmaleimide VIII **enhances** DR5-mediated apoptosis through the MKK4/**JNK**/p38 kinase and the mitochondrial pathways
Author(s): Ohtsuka T; Zhou T (REPRINT)
Corporate Source: Univ Alabama,Dept Med, Div Clin Immunol & Rheumatol,465 LHRB,701 19th St S/Birmingham//AL/35294 (REPRINT); Univ Alabama,Dept Med, Div Clin Immunol & Rheumatol,Birmingham//AL/35294; Sankyo Co Ltd,Biomed Res Labs, Shinagawa Ku,Tokyo 1408710//Japan/
Journal: JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, V277, N32 (AUG 9), P 29294-29303
ISSN: 0021-9258 Publication date: 20020809
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
Language: English Document Type: ARTICLE
Geographic Location: USA; Japan
Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY
Abstract: Bisindolylmaleimide VIII (Bis VIII) has been previously shown to enhance Fas-mediated apoptosis through a protein kinase C-independent mechanism. In the present study, we examined the effect of Bis VIII on apoptosis induced by DR5 (TRAIL-R2), using an agonistic anti-human DR5 monoclonal antibody, TRA-8. Our results demonstrated that Bis VIII was able to enhance the apoptosis-inducing activity of TRA-8 both in vitro and in vivo. The combination of TRA-8 and Bis VIII led to a synergistic and sustained activation of the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase, which was mediated by MAPK kinase 4 and was caspase-8-dependent. The mitochondrial pathway is involved in the synergistic induction of apoptoosis by Bis VIII and TRA-8. Bis VIII alone induced the loss of mitochondrial membrane potential in a caspase-independent fashion without subsequent release of cytochrome c. However, in the presence of Bis VIII, TRA-8 induced more profound loss of mitochondrial membrane potential and release of cytochrome c. These results suggest that the **enhanced** and persistent activation of the **JNK**/p38 and the decreased mitochondrial membrane potential play a crucial role in synergistic induction of the death receptor-mediated apoptosis by Bis VIII. The unique ability of Bis VIII to enhance DR5-mediated apoptosis signal transduction discloses a potential utility of this compound in combination with anti-DR5 antibody in cancer **therapy**.
Identifiers--KeyWord Plus(R): N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; ICE/CED-3 FAMILY PROTEASES; FADD-DEPENDENT APOPTOSIS; TRAIL-INDUCED APOPTOSIS; CYTOTOXIC LIGAND TRAIL; SIGNALING PATHWAY; KAPPA-B; T-CELLS; INDEPENDENT PATHWAYS

11514345 Genuine Article#: 662UR Number of References: 48
Title: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway
Author(s): Ohtsuka T; Buchsbaum D; Oliver P; Makhija S; Kimberly R; Zhou T (REPRINT)
Corporate Source: Univ Alabama,Dept Med,465 LHRB,701 19th St S/Birmingham//AL/35249 (REPRINT); Sankyo Co Ltd,Biomed Res Labs,Tokyo 1408710//Japan/; Univ Alabama,Dept Med Radiobiol,Birmingham//AL/35294; Univ Alabama,Div Gynecol Oncol,Birmingham//AL/35294; Univ Alabama,Dept Math,Birmingham//AL/35294
Journal: ONCOGENE, 2003, V22, N13 (APR 3), P2034-2044
ISSN: 0950-9232 Publication date: 20030403
Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Language: English Document Type: ARTICLE
Geographic Location: USA; Japan
Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY; ONCOLOGY; CELL BIOLOGY; GENETICS & HEREDITY
Abstract: Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through **enhanced** caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the **JNK**/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the **enhanced** activation of the **JNK**/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular **JNK**/p38 and the mitochondrial death pathways with chemotherapy agents would **enhance** the efficacy and selectivity of both agents in cancer **therapy**.
Descriptors--Author Keywords: apoptosis ; TRAIL receptor ; chemotherapy ; JNK ; mitochondria
Identifiers--KeyWord Plus(R): TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; CYTOTOXIC LIGAND TRAIL; BLADDER-CANCER CELLS; N-TERMINAL KINASE; MEDIATED APOPTOSIS; DR5-MEDIATED APOPTOSIS; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; ANTICANCER AGENTS